Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Genmab A/S - American Depositary Shares
(NQ:
GMAB
)
32.68
+0.21 (+0.65%)
Streaming Delayed Price
Updated: 3:18 PM EDT, Sep 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S - American Depositary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
June 27, 2023
From
Genmab
Via
Business Wire
Where Genmab Stands With Analysts
↗
June 26, 2023
Via
Benzinga
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
June 22, 2023
From
Genmab
Via
Business Wire
Expert Ratings for Genmab
↗
June 06, 2023
Via
Benzinga
Recap: Genmab Q1 Earnings
↗
May 10, 2023
Via
Benzinga
How To Attend Genmab Q1 2023 Earnings Conference Call
↗
May 08, 2023
Via
Benzinga
Price Over Earnings Overview: Genmab
↗
April 27, 2023
Via
Benzinga
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
June 09, 2023
From
Genmab
Via
Business Wire
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
May 25, 2023
From
Genmab A/S
Via
Business Wire
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
↗
May 19, 2023
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...
Via
Benzinga
Analyst Ratings for Genmab
↗
April 20, 2023
Via
Benzinga
P/E Ratio Insights for Genmab
↗
April 11, 2023
Via
Benzinga
This Foreboding Sign Looms Over Genmab's Chart
↗
March 31, 2023
Via
Benzinga
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
May 19, 2023
From
Genmab A/S
Via
Business Wire
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst
↗
April 24, 2023
Via
Benzinga
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
↗
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From
Genmab
Via
Business Wire
What 4 Analyst Ratings Have To Say About Genmab
↗
March 01, 2023
Via
Benzinga
Earnings Outlook For Genmab
↗
February 21, 2023
Via
Benzinga
Alkermes Stock Sees Rising Relative Price Strength
↗
February 17, 2023
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.
Via
Investor's Business Daily
Moderna Stock Getting Closer To Key Technical Benchmark
↗
February 10, 2023
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.
Via
Investor's Business Daily
Anavex Life Sciences Stock Shows Improved Price Strength Rating
↗
February 07, 2023
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.
Via
Investor's Business Daily
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
↗
January 19, 2023
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
Via
Investor's Business Daily
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
↗
January 11, 2023
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
3 Biotech Companies to Watch in 2023
↗
January 06, 2023
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.
Via
InvestorPlace
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
December 21, 2022
From
Genmab A/S
Via
Business Wire
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
↗
December 14, 2022
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.
Via
Investor's Business Daily
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
December 11, 2022
From
Genmab A/S
Via
Business Wire
Our 7 Top Biotech Stock Picks for 2023
↗
December 09, 2022
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023.
Via
InvestorPlace
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
↗
December 08, 2022
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.
Via
Investor's Business Daily
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
